GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Notes Receivable

Fortrea Holdings (FRA:K67) Notes Receivable : €0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Notes Receivable?

Fortrea Holdings's Notes Receivable for the quarter that ended in Mar. 2024 was €0 Mil.


Fortrea Holdings Notes Receivable Historical Data

The historical data trend for Fortrea Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Notes Receivable Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - -

Fortrea Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Fortrea Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Fortrea Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortrea Holdings (FRA:K67) Business Description

Traded in Other Exchanges
Address
8 Moore Drive, Durham, NC, USA, 27709
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings (FRA:K67) Headlines

No Headlines